Medtech Insight Perspectives
Wishes for 2026 from our medtech experts focused on value-based care, faster reimbursements, and better collaboration. Key ideas included enhancing patient engagement, reducing waste, and aligning coverage policies to improve health outcomes and innovation.
AI in medtech offers exciting potential for improving patient care and operational efficiency, but faces significant regulatory challenges. Ensuring data quality and building trust among users are essential for successful AI integration in healthcare, our expert panel said.
As medtech moves toward 2026, experts highlight increased regulatory complexities, particularly around AI, cybersecurity, and device user fees. Urgent regulatory updates are needed to keep pace with rapid technology changes while ensuring patient safety and operational efficiency.
Our experts said investor confidence in medtech is recovering as we head into 2026. Expect larger, selective fundraising and heightened M&A activity, focusing on innovative firms in neurology, cardiovascular health, and AI-driven technologies. Companies with solid strategies are favored.
As our experts know, the geopolitical and macroeconomic uncertainties reshaping the medtech industry make resilience and innovation more important than ever. Companies are onshoring to sidestep supply chain fragility prompts onshoring, while healthcare systems demand proven value.
Opinions on the medtech industry’s high and low points in 2025 varied. Some experts celebrated innovations and increased investments, while others highlighted negative aspects like staff cuts and challenges at the FDA.
The EU's medtech regulatory landscape is shifting, influenced by the Commission's proposed changes. Experts note opportunities and concerns emerging from these reforms, highlighting the need for transparency, efficiency, and adaptability to new technologies by 2026.
India’s medical devices industry entered 2026 on the back of steady market growth amid industry warnings over policy inconsistency and ongoing import dependence.
Medtech enters 2026 with momentum but unease. AI gained traction in diagnostics and development, IPOs reopened, and strategies returned for data-backed platforms. But tariffs, FDA shifts, reimbursement lag and macro volatility now make regulatory stability and disciplined investment critical.
A forward-looking view of prospects for regulatory and market access improvement from the UK’s biggest medtech industry lobby group, the Association of British HealthTech Industries (ABHI).
As 2025 turns to 2026, Swiss medtechs are anxiously looking to the future on three major fronts, according to Daniel Delfosse, head of regulation and innovation at the national industry association, Swiss Medtech.
As AI tools make research fraud and résumé fraud easier than ever, life sciences companies need to take steps to protect themselves. Snedden Campbell CEO Ivor Campbell has some tips on successful strategies.
As it celebrates 75 years shaping the medtech industry, Medtronic invited Medtech Insight to its Minneapolis headquarters to get a closer look at the company’s past, what it’s working on now, and what’s on the horizon.
Our dozen-plus experts from across the medtech sector agreed that 2024 was the year when AI went mainstream. They expect it to continue shaping the sector into 2025 and also hope for increased international harmonization, a more business-friendly US government, and increased investment.
From regulations to technology to market dynamics, 2024 was a year of change for the device sector. We asked 14 experts from industry, regulators and other stakeholders to tell us which changes were welcome, and which they’d like to leave in the past.
Key challenges for 2025 remain enforcement, political issues and potential deregulation, while improved reimbursement and emerging markets offer major advantages. See what else was top of mind for experts contacted by Medtech Insight.
The incoming second Trump administration promises changes for medtech that include both the potential benefits of deregulation and the risks of tariffs. See what a dozen-plus industry experts had to say.
The medtech sector in the UK, Switzerland, and Germany face a challenging 2025, heads of national trade groups say. Competition and access to innovation remain key concerns across the board, with collaboration with the EU and US planned in Switzerland while Germany focuses on approaching elections.
Medtech Insight spoke to eight well-known EU regulatory experts to find out what developments they expect to see, what they fear and their wish list for 2025.
Medtech Insight asked three leading AI experts, Verily’s Andrew Trister, Ferrum Health’s Pelu Tran and Hologic’s Jennifer Schneiders, to offer their perspectives on the future of AI in health care.